{
    "paper_id": "8f1ee8609457c4fe81616669438e50a87d2c5ac2",
    "metadata": {
        "title": "Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas",
        "authors": [
            {
                "first": "Eric",
                "middle": [],
                "last": "Salazar",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Katherine",
                "middle": [
                    "K"
                ],
                "last": "Perez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Madiha",
                "middle": [],
                "last": "Ashraf",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Jian",
                "middle": [],
                "last": "Chen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Brian",
                "middle": [],
                "last": "Castillo",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Paul",
                "middle": [
                    "A"
                ],
                "last": "Christensen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Taryn",
                "middle": [],
                "last": "Eubank",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "David",
                "middle": [
                    "W"
                ],
                "last": "Bernard",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Todd",
                "middle": [
                    "N"
                ],
                "last": "Eagar",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "S",
                "middle": [
                    "Wesley"
                ],
                "last": "Long",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Sishir",
                "middle": [],
                "last": "Subedi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Randall",
                "middle": [
                    "J"
                ],
                "last": "Olsen",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Christopher",
                "middle": [],
                "last": "Leveque",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Mary",
                "middle": [
                    "R"
                ],
                "last": "Schwartz",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Monisha",
                "middle": [],
                "last": "Dey",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Cheryl",
                "middle": [],
                "last": "Chavez-East",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "John",
                "middle": [],
                "last": "Rogers",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Ahmed",
                "middle": [],
                "last": "Shehabeldin",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "David",
                "middle": [],
                "last": "Joseph",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Guy",
                "middle": [],
                "last": "Williams",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Karen",
                "middle": [],
                "last": "Thomas",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Faisal",
                "middle": [],
                "last": "Masud",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Christina",
                "middle": [],
                "last": "Talley",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Research Institute",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Katharine",
                "middle": [
                    "G"
                ],
                "last": "Dlouhy",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Research Institute",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Bevin",
                "middle": [],
                "last": "Valdez Lopez",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Research Institute",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Curt",
                "middle": [],
                "last": "Hampton",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Research Institute",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Jason",
                "middle": [],
                "last": "Lavinder",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Texas at Austin",
                    "location": {
                        "settlement": "Austin",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Jimmy",
                "middle": [
                    "D"
                ],
                "last": "Gollihar",
                "suffix": "",
                "affiliation": {
                    "laboratory": "CCDC Army Research Laboratory-South",
                    "institution": "University of Texas at Austin",
                    "location": {
                        "settlement": "Austin",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Andre",
                "middle": [
                    "C"
                ],
                "last": "Maranhao",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Texas at Austin",
                    "location": {
                        "settlement": "Austin",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Gregory",
                "middle": [
                    "C"
                ],
                "last": "Ippolito",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Texas at Austin",
                    "location": {
                        "settlement": "Austin",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Matthew",
                "middle": [
                    "Ojeda"
                ],
                "last": "Saavedra",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Weill Cornell Medical College",
                    "location": {
                        "settlement": "New York",
                        "region": "New York"
                    }
                },
                "email": ""
            },
            {
                "first": "Concepcion",
                "middle": [
                    "C"
                ],
                "last": "Cantu",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Research Institute",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Prasanti",
                "middle": [],
                "last": "Yerramilli",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Research Institute",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "Layne",
                "middle": [],
                "last": "Pruitt",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Research Institute",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            },
            {
                "first": "James",
                "middle": [
                    "M"
                ],
                "last": "Musser",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Houston Methodist Hospital",
                    "location": {
                        "settlement": "Houston",
                        "region": "Texas"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "The coronavirus disease 2019 (COVID-19) pandemic has spread globally and caused massive loss of life and economic hardship. As of May 2, 2020, there were 3,494,671 confirmed cases and 246,475 deaths worldwide, and in the United States, there were 1,154,340 confirmed cases, and 67,447 deaths. 1 The disease is caused by SARS-CoV-2, a highly transmissible coronavirus first identified in Wuhan, China. [2] [3] [4] SARS-CoV-2 continues to spread in many countries, [5] [6] [7] [8] [9] and despite aggressive research, no proven therapies have been described.",
            "cite_spans": [
                {
                    "start": 293,
                    "end": 294,
                    "text": "1",
                    "ref_id": null
                },
                {
                    "start": 401,
                    "end": 404,
                    "text": "[2]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 405,
                    "end": 408,
                    "text": "[3]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 409,
                    "end": 412,
                    "text": "[4]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 463,
                    "end": 466,
                    "text": "[5]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 467,
                    "end": 470,
                    "text": "[6]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 471,
                    "end": 474,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 475,
                    "end": 478,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 479,
                    "end": 482,
                    "text": "[9]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Treatment strategies for critically ill COVID-19 patients are lacking with only limited evidence available for a battery of anti-viral, antibiotic, and anti-inflammatory agents and aggressive supportive therapy. Multiple clinical trials are ongoing, including the repurposing of remdesivir, an anti-viral investigated to treat Ebola, and hydroxychloroquine (HCQ), an antimalarial chloroquine derivative used to treat lupus and rheumatoid arthritis. There are early anti-COVID-19 efficacy data with remdesivir, 10 and preliminary data supporting the use of HCQ, alone or in combination with azithromycin (AZM), 11 has since been shown by larger controlled trials as misleading and potentially dangerous. 12 New therapies are needed to improve outcomes for critically ill COVID-19 patients.",
            "cite_spans": [
                {
                    "start": 510,
                    "end": 512,
                    "text": "10",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "In convalescent plasma therapy, blood plasma from a recovered patient is collected and transfused to a symptomatic patient. The transfer of convalescent plasma is an old concept, improvement in pulmonary lesions based on computed tomography (CT) scan. 19 A second study by Duan et al. reported improved clinical outcomes in 10 patients who received a single transfusion of convalescent plasma, and no adverse events reported. 18 Two additional small case studies of five and six patients have since been published with similar findings. 20,21 A more recent study by Zeng et. al. suggested that administration of convalescent plasma late in the disease course was ineffective for mortality reduction. 22 We performed the present study to provide additional data on these initial clinical observations of patients' clinical course and subsequent improvement after receiving convalescent plasma therapy for COVID-19. We transfused 25 COVID-19 patients with severe and/or life-threatening disease at the Houston Methodist hospitals, a large, quaternary-care hospital system that serves metropolitan Houston, Texas (~7 million people). 23 Patients were transfused once with 300 mL of convalescent plasma. The therapy was well-tolerated and no transfusion-related adverse events were observed. At day 7 post-transfusion, nine of 25 patients (36%) had improvement in the assessed clinical endpoints. By 14 days post-transfusion, 19 patients (76%) had improved or been discharged. Although our study has limitations, the data indicate that transfusion of convalescent plasma is a safe treatment option for those with severe COVID-19 disease.",
            "cite_spans": [
                {
                    "start": 252,
                    "end": 254,
                    "text": "19",
                    "ref_id": null
                },
                {
                    "start": 426,
                    "end": 428,
                    "text": "18",
                    "ref_id": null
                },
                {
                    "start": 700,
                    "end": 702,
                    "text": "22",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "CoV 28 and binds to the RBD of SARS-CoV-2 with a binding affinity of 6.3 nM. 29 Binding was performed at RT for 1 hr. Plates were washed and anti-human IgG Fab HRP (Sigma A0293, 1:5000) was added to the plate (50 \u00b5L), and incubated at RT for 30 min. Plates were washed 3X with PBST, ELISA substrate (1-step Ultra TMB, Thermo Scientific cat# 34028) was added, plates were developed for 1 min for RBD and 5 min for spike ECD, and the reaction was stopped with 50 \u00b5L of H2SO4. Plates were read at 450 nm absorbance. Three-fold serial dilutions from 50 to 4050 were analyzed. Titer was defined as the last dilution showing an optical density greater than a multi-plate negative control average plus six standard deviations.",
            "cite_spans": [
                {
                    "start": 77,
                    "end": 79,
                    "text": "29",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Libraries for whole viral genome sequencing were prepared according to version 1 ARTIC nCoV-2019 sequencing protocol (https://artic.network/ncov-2019). Long reads were generated with the LSK-109 sequencing kit, 24 native barcodes (NBD104 and NBD114 kits), and a GridION instrument (Oxford Nanopore). Short reads were generated with the NexteraXT kit and a MiSeq or NextSeq 550 instrument (Illumina). Whole genome alignments of consensus viral genome sequence generated from the ARTIC nCoV-2019 bioinformatics pipeline were trimmed to the start of orf1ab and the end of orf10 and used to generate a phylogenetic tree using RAxML (https://cme.h-its.org/exelixis/web/software/raxml/index.html) to determine viral clade.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SARS-CoV-2 Genome Sequencing and Analysis"
        },
        {
            "text": "Trees were visualized and annotated with CLC Genomics Workbench v20 (Qiagen). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SARS-CoV-2 Genome Sequencing and Analysis"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.08.20095471 doi: medRxiv preprint hypertension (9 patients), hyperlipidemia (5 patients), and gastrointestinal reflux disease (GERD, 4 patients). The majority of patients (19 of 25, 76%) enrolled in the study had O-positive blood type. Bacterial or viral co-infections were identified in five patients (Table 1) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 409,
                    "end": 418,
                    "text": "(Table 1)",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "Overview of Patient Characteristics"
        },
        {
            "text": "The characteristics of the donors of convalescent plasma are shown in Table 2 . A total of nine donors provided plasma that was used to transfuse COVID-19 patients; two donors gave plasma on multiple occasions. The donors ranged in age from 23 to 67 years, and 56% (5/9) were males. On average, the donors gave plasma 26 days (range 19-33) from their symptom start date and 21 days (range 13 to 27 days) from their initial positive RT-PCR specimen collection date. Although all donors had been symptomatic, only one was ill enough to require hospitalization. To assess antibody titers, we used two ELISAs, one based on recombinant purified ectodomain (ECD) of the spike protein and the second using recombinant receptor binding domain (RBD) of the spike protein. The titers of the convalescent plasma used for transfusion ranged from 0 to 1350 for the RBD and ECD domains (Figure 1 and Table S1 ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 70,
                    "end": 77,
                    "text": "Table 2",
                    "ref_id": "TABREF3"
                },
                {
                    "start": 872,
                    "end": 881,
                    "text": "(Figure 1",
                    "ref_id": "FIGREF2"
                },
                {
                    "start": 886,
                    "end": 894,
                    "text": "Table S1",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "Donor Characteristics"
        },
        {
            "text": "The median time from symptom onset to hospitalization was 6 days [IQR 4 to 8 days] ( Table 3) .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 85,
                    "end": 93,
                    "text": "Table 3)",
                    "ref_id": "TABREF5"
                }
            ],
            "section": "Transfusion of Severe COVID-19 Patients with Convalescent-Phase Donor Plasma"
        },
        {
            "text": "The majority of patients received concomitant anti-inflammatory treatments within five days of the plasma transfusion, including tocilizumab and steroids. Most received other investigational treatments, including courses of HCQ and AZM, ribavirin, and/or lopinavir/ritonavir, and two patients received remdesivir ( Table 3) . All patients required oxygen support prior to transfusion (Figure 1) , including 12 patients on mechanical ventilation, 10 on low-flow oxygen, and 3 on high-flow oxygen. One patient (patient 9) was placed on ECMO on the day of transfusion prior to transfusion. More than half (13/25, 52%) had acute respiratory distress syndrome (ARDS) 30 at the time of transfusion ( Table 3 ). The median time from symptom onset to transfusion was 10 days [IQR, 7.5 to 12.5], and from hospitalization to transfusion was 2 days [IQR, 2 to 4] (Table All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 315,
                    "end": 323,
                    "text": "Table 3)",
                    "ref_id": "TABREF5"
                },
                {
                    "start": 384,
                    "end": 394,
                    "text": "(Figure 1)",
                    "ref_id": "FIGREF2"
                },
                {
                    "start": 694,
                    "end": 701,
                    "text": "Table 3",
                    "ref_id": "TABREF5"
                }
            ],
            "section": "Transfusion of Severe COVID-19 Patients with Convalescent-Phase Donor Plasma"
        },
        {
            "text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Transfusion of Severe COVID-19 Patients with Convalescent-Phase Donor Plasma"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.08.20095471 doi: medRxiv preprint There was a trend toward increasing ferritin by day 3, which tended to decrease by day 7. No significant increases in liver enzymes were noted ( Table 4 and Table S3 ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 286,
                    "end": 306,
                    "text": "Table 4 and Table S3",
                    "ref_id": "TABREF5"
                }
            ],
            "section": "Transfusion of Severe COVID-19 Patients with Convalescent-Phase Donor Plasma"
        },
        {
            "text": "A recent analysis of the genomic heterogeneity of the SARS-CoV-2 virus strains circulating in Houston, Texas, early in the pandemic showed that the predominant clades isolated were A2a, B, and B1. 32 Amino acid polymorphisms, especially in the spike protein, can potentially alter the character of the antibody response and virulence profile of the virus. 33-36 Therefore, we sequenced the genomes of the SARS-CoV-2 virus strains infecting donors and recipients to assess the magnitude of nucleotide and amino acid mismatch between the viral genotype of donors and plasma recipients. Of the 34 patients and donors, we were able to analyze all plasma recipient genotypes and four donor genotypes. Overall, there were few polymorphisms in the sequenced viruses, and there was no correlation between infecting strains and disease severity ( Figure S1 ). Analysis of the first four donors found that, in general, donor and recipient S proteins matched when their SARS-CoV2 isolates were from the same clade ( Figure S1 ). This is primarily a result of a D614G amino acid change in S protein that defines the clade A2a. 32,37 However, there are at least three instances of an additional amino acid change in the S2 domain of the S protein, 34-36 one in a donor (M731I) and two in recipients (S967R and L1203F) ( Figure S1 ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 838,
                    "end": 847,
                    "text": "Figure S1",
                    "ref_id": "FIGREF2"
                },
                {
                    "start": 1005,
                    "end": 1014,
                    "text": "Figure S1",
                    "ref_id": "FIGREF2"
                },
                {
                    "start": 1307,
                    "end": 1316,
                    "text": "Figure S1",
                    "ref_id": "FIGREF2"
                }
            ],
            "section": "Viral Genome Sequencing of SARS-CoV-2 Strains from Recipients and Donors"
        },
        {
            "text": "Our study was performed to evaluate the safety and potential benefit of transfusing convalescent plasma to patients with severe COVID-19 disease. To date, this is the largest cohort assessed for outcomes pertaining to convalescent plasma transfusion for COVID-19. Of our 25 patients, nine showed improvement by day 7, and by day 14 post-transfusion, 19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "patients showed improvement, as assessed by discharge or at least a 1-point improvement on a modified clinical scale. Several case studies investigating the use of convalescent plasma to All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.08.20095471 doi: medRxiv preprint treat severe COVID-19 have recently been published 18-22 and the overall findings presented herein are consistent with these reports.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "Convalescent plasma therapy has been administered on the front lines during emergencies, and we and others recognize the need for controlled clinical trials to determine its therapeutic efficacy. 14, 15, 19, 38, 39 The timing of the transfusion post-symptom onset, the number of transfusions, the volume and its adjustment based on BMI, donor antibody titers, and other parameters need to be evaluated to optimize this therapy. For example, some studies have observed that the sooner after the onset of symptoms that the transfusion was administered, the better the outcomes. 14, 15, 39 Variability existed among our cohort with respect to symptom onset and severity of illness.",
            "cite_spans": [
                {
                    "start": 196,
                    "end": 199,
                    "text": "14,",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 200,
                    "end": 203,
                    "text": "15,",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 204,
                    "end": 207,
                    "text": "19,",
                    "ref_id": null
                },
                {
                    "start": 208,
                    "end": 211,
                    "text": "38,",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 212,
                    "end": 214,
                    "text": "39",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 576,
                    "end": 579,
                    "text": "14,",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 580,
                    "end": 583,
                    "text": "15,",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 584,
                    "end": 586,
                    "text": "39",
                    "ref_id": "BIBREF20"
                }
            ],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The anti-SARS-CoV2 anti-spike protein IgG titers varied significantly among individual donors, as assessed by ELISA (Table S1 ). Early in the study period, ELISA titers were not available, and thus, transfusions were given solely on the basis of ABO compatibility. Among the five patients who received plasma from a donor with an anti-RBD IgG titer of \u226450, one is The results from our study support the existing data from the COVID-19 literature that point to underlying medical conditions, such as obesity, type 2 diabetes, and hypertension, playing a large role in patients' COVID-19 disease course and outcomes. [40] [41] [42] Sixty-eight percent (17/25) of transfused patients in this study had a BMI in the obese category and 84% were considered overweight. All rights reserved. No reuse allowed without permission.",
            "cite_spans": [
                {
                    "start": 615,
                    "end": 619,
                    "text": "[40]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 620,
                    "end": 624,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 625,
                    "end": 629,
                    "text": "[42]",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 116,
                    "end": 125,
                    "text": "(Table S1",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "Discussion"
        },
        {
            "text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.08.20095471 doi: medRxiv preprint A confounding variable in many convalescent plasma studies is the addition of other treatment regimens, such as antivirals and anti-inflammatory compounds. Adjunct therapies hinder the ability to draw definitive conclusions regarding the contribution of the convalescent plasma. In our study, all 25 patients received HCQ and AZM, as these were reported to have beneficial effects early in the pandemic. 11 Subsequent larger and more controlled studies determined that this combination has no benefits to patients, and in fact, could be harmful. 12",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "Many (68%) of our patients were also administered oral ribavirin. Despite inconclusive data on ribavirin's efficacy in the treatment of SARS during the 2003 epidemic, 43 proven safety and ready availability supported its use in the treatment of our COVID-19 patients. Two patients received remdesivir, which was recently shown to modestly reduce recovery time. 10,44 Antiinflammatory compounds, such as the IL-6 inhibitor tocilizumab and methylprednisolone, were administered per institutional protocols within five days of the plasma transfusion to 72% of our cohort. Tocilizumab was recently shown to reduce mortality in a retrospective analysis of 20 severe COVID-19 patients. 45 Because convalescent plasma therapy is typically performed in emergency situations for the very ill, it is difficult to assess its benefits as a standalone treatment. A blinded, randomized controlled trial is currently being considered.",
            "cite_spans": [
                {
                    "start": 680,
                    "end": 682,
                    "text": "45",
                    "ref_id": "BIBREF22"
                }
            ],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The patient outcomes in our study are similar to those recently published describing treating COVID-19 patients with remdesivir on a compassionate-use basis. 10 In that review, patients were prescribed a 10-day course of remdesivir with follow up for 28 days or until discharge or death. Both study cohorts included patients who required invasive ventilation, (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [
                {
                    "start": 158,
                    "end": 160,
                    "text": "10",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.08.20095471 doi: medRxiv preprint mortality difference between the cohorts cannot be compared as the remdesivir cohort represented an older population (median age of 64 years, versus 51 years in our study), where the risk of death was greater at baseline. Delays in obtaining remdesivir on a compassionate use basis (12 days from symptom onset) may have artificially extended the cohort's opportunity to demonstrate clinical improvement and does not reflect the eligibility criteria for any ongoing clinical trials. [46] [47] [48] Clinical outcomes data to inform timing of therapeutic interventions like remdesivir or convalescent plasma are lacking.",
            "cite_spans": [
                {
                    "start": 623,
                    "end": 627,
                    "text": "[46]",
                    "ref_id": null
                },
                {
                    "start": 628,
                    "end": 632,
                    "text": "[47]",
                    "ref_id": null
                },
                {
                    "start": 633,
                    "end": 637,
                    "text": "[48]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "We analyzed the genomes of the infecting SARS-CoV-2 strain from both the donors and recipients. One could conceive of a situation in which the donor genotype of the SARS-CoV-2 infecting strain was matched with the genotype of the patient's strain to maximize potential immune benefit. We found few differences in the inferred amino acid sequences of the plasma donor and recipient strains, and no association between disease severity and infecting strain genotype.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "The majority of the donors and plasma recipients in our study had type O blood (25/34, 74%). Our initial donors, who donated repeatedly, were blood type O. Since ABO-compatibility was a requirement for recipient selection early in the study, many of our early recipients were also type O. Zhao et al. have reported that of the 2,173 patients analyzed in their study of COVID-19 patients in China, the majority had type A blood. 49 More studies are needed to determine if this association holds true in geographically-distinct areas of infection. Regardless, our data do not reflect a higher rate of blood type A in COVID-19 patients.",
            "cite_spans": [
                {
                    "start": 289,
                    "end": 300,
                    "text": "Zhao et al.",
                    "ref_id": null
                },
                {
                    "start": 428,
                    "end": 430,
                    "text": "49",
                    "ref_id": "BIBREF26"
                }
            ],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "As with the great majority of the studies using convalescent plasma to treat severe infections, our study has several important limitations. First, the study was a small case series and no control group was included. Thus, it is not clear if the 25 patients given convalescent plasma would have improved without this treatment. Second, all patients were treated with multiple other medications, including antiviral and anti-inflammatory agents. Thus, we cannot conclude All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Limitations"
        },
        {
            "text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Limitations"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.08.20095471 doi: medRxiv preprint that the patient outcomes were solely due to administration of convalescent plasma. Third, 24 of the 25 patients received only one transfusion of plasma. Whether treatment with multiple transfusions on one or more days would be a more effective regimen is not clear. An expanded donor pool providing higher-titer convalescent plasma would allow for dose escalation studies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Limitations"
        },
        {
            "text": "Fourth, many patients had severe COVID-19 disease. It is possible that transfusion of convalescent plasma earlier in the course of disease or in patients with less severe symptoms would be a better approach. Fifth, our plasma donors had a range of anti-S protein IgG titers.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Limitations"
        },
        {
            "text": "Several patients were transfused with plasma with very low titer of anti-S protein antibody. Sixth, the small number of patients treated, coupled with the experimental design, did not permit us to determine if this therapy significantly reduces mortality or other measures of disease outcome.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Limitations"
        },
        {
            "text": "Finally, while this study assessed outcomes at days 7 and 14 post-transfusion, it is important to note that at the time of this writing, all but two of the surviving patients that were intubated had been extubated. Similarly, all patients that were on ECMO had been weaned, and 20 of the 25 patients had been discharged.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Limitations"
        },
        {
            "text": "Outcomes from this case series of 25 patients indicates that administration of convalescent plasma is a safe treatment option for those with severe COVID-19 disease. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concluding Statement"
        },
        {
            "text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concluding Statement"
        },
        {
            "text": "(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concluding Statement"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concluding Statement"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.08.20095471 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concluding Statement"
        },
        {
            "text": "The copyright holder for this preprint this version posted May 13, 2020. . https://doi.org/10.1101/2020.05.08.20095471 doi: medRxiv preprint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Concluding Statement"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497--506",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Pei",
                    "middle": [
                        "S"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "368",
            "issn": "",
            "pages": "489--93",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "A novel coronavirus outbreak of global health concern",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "W"
                    ],
                    "last": "Horby",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "F"
                    ],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "470--473",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Caly",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Druce",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Roberts",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Med J Aust",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.5694/mja2.50569"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ghosal",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Sengupta",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Majumder",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Sinha",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Spread of SARS-CoV-2 in the Icelandic Population",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Gudbjartsson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Helgason",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Jonsson",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2006100"
                ]
            }
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Preliminary case report on the SARS-CoV-2 cluster in the UK",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "B"
                    ],
                    "last": "Hodcroft",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Magagnoli",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Narendran",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Pereira",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.04.16.20065920"
                ]
            }
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "C"
                    ],
                    "last": "Luke",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Kilbane",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Jackson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Hoffman",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Ann Intern Med",
            "volume": "145",
            "issn": "",
            "pages": "599--609",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "O"
                    ],
                    "last": "Soo",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Clin Microbiol Infect",
            "volume": "10",
            "issn": "",
            "pages": "676--684",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Use of convalescent plasma therapy in SARS patients in Hong Kong",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "O"
                    ],
                    "last": "Soo",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Eur J Clin Microbiol Infect Dis",
            "volume": "24",
            "issn": "",
            "pages": "44--50",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "F"
                    ],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "K"
                    ],
                    "last": "To",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "K"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Clin Infect Dis",
            "volume": "52",
            "issn": "",
            "pages": "447--56",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Walls",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "J"
                    ],
                    "last": "Park",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Tortorici",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wall",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "T"
                    ],
                    "last": "Mcguire",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Veesler",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell",
            "volume": "181",
            "issn": "",
            "pages": "281--92",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Structural and Functional Basis of SARS-CoV-2 Entry by",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Using Human ACE2",
            "authors": [],
            "year": 2020,
            "venue": "Cell",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.cell.2020.03.045"
                ]
            }
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wrapp",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Corbett",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "367",
            "issn": "",
            "pages": "1260--1263",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Global initiative on sharing all influenza data -from vision to reality",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Shu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mccauley",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Gisaid",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Euro Surveill",
            "volume": "22",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Convalescent plasma as a potential therapy for COVID",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Bao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "The effectiveness of convalescent etiology: a systematic review and exploratory meta-analysis",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mair-Jenkins",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Saavedra-Campos",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "K"
                    ],
                    "last": "Baillie",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Infect Dis",
            "volume": "211",
            "issn": "",
            "pages": "80--90",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Clinical characteristics of fatal and recovered cases of",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Effective treatment of severe COVID-19 patients with tocilizumab",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Proc Natl Acad Sci",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1073/pnas.2005615117.46"
                ]
            }
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "GS-5734\u2122) in Participants With Severe Coronavirus Disease (COVID-19)",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Remdesivir",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "National Institutes of Health. Adaptive COVID-19 Treatment Trial (ACTT)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.11.20031096"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "deceased, and one was placed on ECMO. The patient placed on ECMO received a second dose of convalescent plasma confirmed to have high IgG titer prior to transfusion. The patient was eventually extubated and weaned off ECMO. Regardless, at this time, no clear correlation between ELISA IgG titer and patient outcomes can be established in this small patient cohort. In addition, more studies are needed to better understand why donors present with a range of antispike antibody titers, and whether there is a correlation between donor disease presentation and antibody titers. Additional studies are underway to better understand the correlation between anti-SARS-CoV-2 antibody titers and virus neutralization.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "including 35 of 53 (66%) of remdesivir patients compared to 17 of 25 (68%) of the patients in our study. Clinical improvement was less frequent among patients who received invasive ventilation at any time or were 70 years of age or older. In the remdesivir study, 36 of 53 patients (68%) showed clinical improvement at follow up (median time to follow up, 18 days), while 19 of 25 patients (76%) receiving convalescent plasma improved by day 14 posttransfusion. These data suggest that treatment with convalescent plasma and remdesivir resulted in similar outcomes among patients based on oxygenation requirements and age. The All rights reserved. No reuse allowed without permission.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Respiratory support status, clinical score, patient outcomes (discharge/death), and RBD titer of transfused plasma in 25-patient cohort. Respiratory support requirements for the duration of hospitalization are color coded per the key. Discharge or death are indicated by open and filled squares, respectively. Patient 16 was given a second transfusion on day 6, indicated by a vertical line. The convalescent plasma titers for the RBD domain of the SARS-CoV-2 spike protein are indicated to the left. NIPPV, non-invasive, positive-pressure ventilation; NC, nasal cannula; ECMO, extracorporeal membrane oxygen.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Clinical outcomes at day 7 and 14 post-transfusion. The table shows the distribution of patients on low-flow, high-flow, invasive, or no oxygen support at days 0 (day of transfusion), 7, and 14. By day 7 post-transfusion, 36% (9/25) of patients had improved from baseline; 76% (19/25) of patients improved by day 14 post-transfusion.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Figure 2",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Twenty-five patients with severe and/or life-threatening COVID-19 disease were enrolled in the study from March 28 -April 14, 2020. Patients ranged in age from 19 to 77 years (median 51, All rights reserved. No reuse allowed without permission.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Demographics and Clinical Characteristics of Patients with COVID-19 Disease who Received Convalescent Plasma.",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Characteristics of Convalescent Plasma Donors.",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "Disease Course and Additional Treatments of Patients Receiving Convalescent Plasma. Abbreviations: ARDS, acute respiratory distress syndrome; CRRT, cardiac rapid response team; ECMO (VV), extracorporeal mechanical oxygenation (veno-venous); IFN, Interferon; HCQ, hydroxychloroquine; AZM, azithromycin; RBV, ribavirin; LPVr, lopinavir/ritonavir; NA, still hospitalized at day 14 post-transfusion (study endpoint).",
            "latex": null,
            "type": "table"
        },
        "TABREF6": {
            "text": "Median Laboratory Values of Plasma Recipients at Days 0, 7, and 14 Post-Transfusion.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}